None of the 29 investors followed here reported a position in GPCR in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a GPCR trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 31, 2026 | Lin XichenOfficer | Conversion of Exercise of derivative security at price 0.34 per share. | 17.8K | $6.06K |
| Aug 17, 2026 | Lin XichenOfficer | Conversion of Exercise of derivative security at price 0.34 per share. | 11.8K | $4.02K |
| Aug 5, 2026 | Berrios John JosephOfficer | Stock Award(Grant) at price 0.00 per share. | 140.8K | — |
| Aug 3, 2026 | Lin XichenOfficer | Conversion of Exercise of derivative security at price 0.34 per share. | 11.8K | $4.02K |
| Jul 13, 2026 | Lin XichenOfficer | Conversion of Exercise of derivative security at price 50.59 per share. | 23.6K | $1.20M |
| Jun 24, 2026 | Lin XichenOfficer | Conversion of Exercise of derivative security at price 0.34 per share. | 23.6K | $8.04K |
| Apr 14, 2026 | Lang MatthewChief Operating Officer | Stock Award(Grant) at price 0.00 per share. | 184.6K | — |
| Mar 18, 2026 | Stevens Raymond CChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 260.2K | — |
| Mar 18, 2026 | Hall AshleyOfficer | Stock Award(Grant) at price 0.00 per share. | 47.7K | — |
| Mar 18, 2026 | Ma YingliChief Technology Officer | Stock Award(Grant) at price 0.00 per share. | 32.5K | — |
| Mar 18, 2026 | Lin XichenOfficer | Stock Award(Grant) at price 0.00 per share. | 43.4K | — |
| Mar 18, 2026 | Yoon JunChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 104.1K | — |
| Mar 18, 2026 | Coll Crespo BlasOfficer | Stock Award(Grant) at price 0.00 per share. | 75.9K | — |
| Jun 30, 2025 | Stevens Raymond CChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 89.7K | — |
| Jun 30, 2025 | Ma YingliChief Technology Officer | Stock Award(Grant) at price 0.00 per share. | 24.5K | — |
| Jun 30, 2025 | Lin XichenOfficer | Stock Award(Grant) at price 0.00 per share. | 57.1K | — |
| Jun 30, 2025 | Yoon JunChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 39.6K | — |
| Jun 30, 2025 | Coll Crespo BlasOfficer | Stock Award(Grant) at price 0.00 per share. | 8K | — |
| Mar 13, 2025 | Stevens Raymond CChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 340.3K | — |
| Mar 13, 2025 | Hall AshleyOfficer | Stock Award(Grant) at price 0.00 per share. | 51K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 27.2 | -28.8 | -23.5 | -14.0 | -5.1 | 36.4 | -10.5 | -4.4 | -31.9 | -25.6 | −66.5% | ||
| 2025 | 10.5 | -20.8 | -27.1 | 56.0 | -19.4 | -4.7 | -14.2 | 8.4 | 45.1 | 19.0 | 7.5 | 94.2 | +156.5% |
| 2024 | 7.0 | -7.0 | 5.6 | -8.0 | -13.3 | 14.8 | -4.8 | 2.0 | 15.1 | -6.2 | -19.4 | -18.2 | −33.5% |
| 2023 | -6.9 | 6.9 | 25.8 | 29.9 | -11.4 | -23.5 | 78.9 | 47.4 | -25.0 | -26.8 | +59.5% |
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Buy / hold / sell counts